Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts

Human Molecular Genetics

Volumn 20, Issue 10, 2011, Pages 2048-2057

  Bastin, Jean ^a,b   Lopes Costa, Alexandra ^a   Djouadi, Fatima ^a,b  

^a INSERM   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE PALMITOYL TRANSFERASE 2; ENZYME; FATTY ACID; MUTANT PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RESVERATROL; SIRTINOL; SIRTUIN 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VERY LONG CHAIN ACYL COA DEHYDROGENASE;

ARTICLE; CARNITINE PALMITOYL TRANSFERASE 2 DISORDER; CELL DAMAGE; CLINICAL ARTICLE; CLINICAL EVALUATION; DOSE TIME EFFECT RELATION; DRUG EXPOSURE; ENZYME INHIBITION; FATTY ACID OXIDATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INBORN ERROR OF METABOLISM; LIPID TRANSPORT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN FIBROBLAST; VERY LONG CHAIN ACYL COA DEHYDROGENASE DISORDER; WESTERN BLOTTING;

ACYL-COA DEHYDROGENASE, LONG-CHAIN; ANTIOXIDANTS; CARNITINE O-PALMITOYLTRANSFERASE; CELLS, CULTURED; ENZYME ACTIVATION; FATTY ACIDS; FIBROBLASTS; GENE EXPRESSION REGULATION; HEAT-SHOCK PROTEINS; HUMANS; MUTATION; OXIDATION-REDUCTION; PROTEIN BINDING; PROTEIN KINASES; SIRTUIN 1; STILBENES; TRANSCRIPTION FACTORS;

RICE STRIPE VIRUS;

EID: 79955442484     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr089     Document Type: Article

References (42)

1. Rinaldo, P., Matern, D. and Bennett, M.J. (2002) Fatty acid oxidation disorders. Annu. Rev. Physiol., 64, 477-502.
2. Vockley, J. and Whiteman, D.A. (2002) Defects of mitochondrial beta-oxidation: a growing group of disorders. Neuromuscul. Disord., 12, 235-246.
3. Bonnefont, J.P., Djouadi, F., Prip-Buus, C., Gobin, S., Munnich, A. and Bastin, J. (2004) Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol. Aspects Med., 25, 495-520.
4. Gregersen, N., Andresen, B.S., Corydon, M.J., Corydon, T.J., Olsen, R.K., Bolund, L. and Bross, P. (2001) Mutation analysis in mitochondrial fatty acid oxidation defects: exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship. Hum. Mutat., 18, 169-189.
5. Angelini, C., Federico, A., Reichmann, H., Lombes, A., Chinnery, P. and Turnbull, D. (2006) Task force guidelines handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disorders. Eur. J. Neurol., 13, 923-929.
6. Corti, S., Bordoni, A., Ronchi, D., Musumeci, O., Aguennouz, M., Toscano, A., Lamperti, C., Bresolin, N. and Comi, G.P. (2008) Clinical features and new molecular findings in carnitine palmitoyltransferase II (CPT II) deficiency. J. Neurol. Sci., 266, 97-103.
7. Andresen, B.S., Olpin, S., Poorthuis, B.J., Scholte, H.R., Vianey-Saban, C., Wanders, R., Ijlst, L., Morris, A., Pourfarzam, M., Bartlett, K. et al. (1999) Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am. J. Hum. Genet., 64, 479-494.
8. Gregersen, N. and Olsen, R.K. (2010) Disease mechanisms and protein structures in fatty acid oxidation defects. J. Inherit. Metab.Dis., 33, 547-553.
9. Gobin-Limballe, S., Djouadi, F., Aubey, F., Olpin, S., Andresen, B.S., Yamaguchi, S., Mandel, H., Fukao, T., Ruiter, J.P., Wanders, R.J. et al. (2007) Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy. Am. J. Hum. Genet., 81, 1133-1143.
10. Thuillier, L., Rostane, H., Droin, V., Demaugre, F., Brivet, M., Khadom, N., Prip-Buus, C., Gobin, S., Saudubray, J.M. and Bonnefont, J.P. (2003) Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 deficiency. Hum. Mutat., 5, 493-501.
11. Spiekerkoetter, U., Bastin, J., Gillingham, M., Morris, A., Wijburg, F. and Wilcken, B. (2010) Current issues regarding treatment of mitochondrial fatty acid oxidation disorders. J. Inherit. Metab. Dis., 33, 555-561.
12. Vockley, J., Singh, R.H. and Whiteman, D.A. (2002) Diagnosis and management of defects of mitochondrial beta-oxidation. Curr. Opin. Clin. Nutr. Metab. Care, 5, 601-609.
13. Djouadi, F., Aubey, F., Schlemmer, D., Ruiter, J.P., Wanders, R.J., Strauss, A.W. and Bastin, J. (2005) Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. Hum. Mol. Genet., 14, 2695-2703.
14. Djouadi, F., Bonnefont, J.P., Thuillier, L., Droin, V., Khadom, N., Munnich, A. and Bastin, J. (2003) Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate. Pediatr. Res., 54, 446-451.
15. Bonnefont, J.P., Bastin, J., Behin, A. and Djouadi, F. (2009) Bezafibrate for treatment of an inborn mitochondrial b-oxidation defect. N. Engl. J. Med., 360, 838-840.
16. Bonnefont, J.P., Bastin, J., Laforet, P., Aubey, F., Mogenet, A., Romano, S., Ricquier, D., Gobin-Limballe, S., Vassault, A., Behin, A. et al. (2010) Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. Clin. Pharmacol. Ther., 88, 101-108.
17. Finck, B.N. and Kelly, D.P. (2006) PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J. Clin. Invest., 116, 615-622.
18. Handschin, C. and Spiegelman, B.M. (2006) Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr. Rev., 27, 728-735.
19. Rodgers, J.T., Lerin, C., Haas, W., Gygi, S.P., Spiegelman, B.M. and Puigserver, P. (2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature, 434, 113-118.
20. Canto, C. and Auwerx, J. (2009) PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipidol., 20, 98-105.
21. Baur, J.A. and Sinclair, D.A. (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug. Discov., 5, 493-506.
22. Borra, M.T., Smith, B.C. and Denu, J.M. (2005) Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem., 280, 17187-17195.
23. Howitz, K.T., Bitterman, K.J., Cohen, H.Y., Lamming, D.W., Lavu, S., Wood, J.G., Zipkin, R.E., Chung, P., Kisielewski, A., Zhang, L.L. et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 425, 191-196.
24. Kaeberlein, M., McDonagh, T., Heltweg, B., Hixon, J., Westman, E.A., Caldwell, S.D., Napper, A., Curtis, R., DiStefano, P.S., Fields, S. et al. (2005) Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem., 280, 17038-17045.
25. Dasgupta, B. and Milbrandt, J. (2007) Resveratrol stimulates AMP kinase activity in neurons. Proc. Natl Acad. Sci. USA, 104, 7217-7222.
26. Hou, X., Xu, S., Maitland-Toolan, K.A., Sato, K., Jiang, B., Ido, Y., Lan, F., Walsh, K., Wierzbicki, M., Verbeuren, T.J. et al. (2008) SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J. Biol. Chem., 283, 20015-20026.
27. Zang, M., Xu, S., Maitland-Toolan, K.A., Zuccollo, A., Hou, X., Jiang, B., Wierzbicki, M., Verbeuren, T.J. and Cohen, R.A. (2006) Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes, 55, 2180-2191.
28. Cool, B., Zinker, B., Chiou, W., Kifle, L., Cao, N., Perham, M., Dickinson, R., Adler, A., Gagne, G., Iyengar, R. et al. (2006) Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell. Metab., 3, 403-416.
29. Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A., Prabhu, V.V., Allard, J.S., Lopez-Lluch, G., Lewis, K. et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 444, 337-342.
30. Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P. et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 127, 1109-1122.
31. McAndrew, R.P., Wang, Y., Mohsen, A.W., He, M., Vockley, J. and Kim, J.J. (2008) Structural basis for substrate fatty acyl chain specificity: crystal structure of human very-long-chain acyl-CoA dehydrogenase. J. Biol. Chem., 283, 9435-9443.
32. Rufer, A.C., Thoma, R., Benz, J., Stihle, M., Gsell, B., De Roo, E., Banner, D.W., Mueller, F., Chomienne, O. and Hennig, M. (2006) The crystal structure of carnitine palmitoyltransferase 2 and implications for diabetes treatment. Structure, 14, 713-723.
33. Gobin-Limballe, S., McAndrew, R.P., Djouadi, F., Kim, J.J. and Bastin, J. (2010) Compared effects of missense mutations in very-long-chain Acyl-CoA dehydrogenase deficiency: combined analysis by structural, functional and pharmacological approaches. Biochim. Biophys. Acta, 1802, 478-484.
34. Smith, J.J., Kenney, R.D., Gagne, D.J., Frushour, B.P., Ladd, W., Galonek, H.L., Israelian, K., Song, J., Razvadauskaite, G., Lynch, A.V. et al. (2009) Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC. Syst. Biol., 3, 31.
35. Gerhart-Hines, Z., Rodgers, J.T., Bare, O., Lerin, C., Kim, S.H., Mostoslavsky, R., Alt, F.W., Wu, Z. and Puigserver, P. (2007) Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J., 26, 1913-1923.
36. Purushotham, A., Schug, T.T., Xu, Q., Surapureddi, S., Guo, X. and Li, X. (2009) Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell. Metab., 9, 327-338.
37. Rodgers, J.T. and Puigserver, P. (2007) Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc. Natl Acad. Sci. USA, 104, 12861-12866.
38. Okazaki, M., Iwasaki, Y., Nishiyama, M., Taguchi, T., Tsugita, M., Nakayama, S., Kambayashi, M., Hashimoto, K. and Terada, Y. (2010) PPARbeta/delta regulates the human SIRT1 gene transcription via Sp1. Endocr. J., 57, 403-413.
39. Jager, S., Handschin, C., St-Pierre, J. and Spiegelman, B.M. (2007) AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA, 104, 12017-12022.
40. Milne, J.C., Lambert, P.D., Schenk, S., Carney, D.P., Smith, J.J., Gagne, D.J., Jin, L., Boss, O., Perni, R.B., Vu, C.B. et al. (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature, 450, 712-716.
41. Feige, J.N., Lagouge, M., Canto, C., Strehle, A., Houten, S.M., Milne, J.C., Lambert, P.D., Mataki, C., Elliott, P.J. and Auwerx, J. (2008) Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab., 8, 347-358.
42. Bastin, J., Aubey, F., Rotig, A., Munnich, A. and Djouadi, F. (2008) Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients' cells lacking its components. J. Clin. Endocrinol. Metab., 93, 1433-1441.